Gentium Receives Marketing Authorization for Defitelio - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gentium Receives Marketing Authorization for Defitelio



Gentium S.p.A. has reported that the European Commission has granted a marketing authorization for Defitelio (R)(defibrotide) for the treatment of severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem-cell transplantation therapy. Defitelio (R) is the first approved treatment in the European Union for this condition. This authorization is the formal endorsement of the positive opinion received from the EMA Committee for Human Medicinal Product on July 26, 2013. Gentium intends to begin commercialization of Defitelio (R) in the EU in December 2013.

Source: Gentium

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here